stockrowImmunityBio, Inc. (IBRX) vs Madrigal Pharmaceuticals, Inc. (MDGL)
- ImmunityBio, Inc. IBRX 8.67 +8.24%
- Madrigal Pharmaceuticals, Inc. MDGL 397.03 −0.77%
ImmunityBio, Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. ImmunityBio, Inc. and Madrigal Pharmaceuticals, Inc. are of similar size ($9.3B and $8.5B). ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 92.8%. Madrigal Pharmaceuticals, Inc. has the higher net margin (−10.9% vs −598.6%) and the lower return on invested capital (−1,480.3% vs 0.00%). Across the 16 metrics below, Madrigal Pharmaceuticals, Inc. leads on 9 and ImmunityBio, Inc. on 7.
Valuation
Profitability
| Metric | IBRX | MDGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.34% | 90.96% | 68.51% |
| Operating margin | (151.88%) | (10.69%) | 0.00% |
| Net margin | (598.56%) | (10.89%) | 0.00% |
| Free cash flow margin | (173.76%) | (11.81%) | 0.00% |
| Return on equity | 122.85% | (24.82%) | (51.96%) |
| Return on assets | (192.58%) | (11.12%) | (46.06%) |
| Return on invested capital | 0.00% | (1,480.32%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack